Dynavax Technologies announces management changes and executive transition

Dynavax Technologies Corp (NASDAQ:DVAX), a $1.16 billion biotech company with a "GOOD" financial health rating according to InvestingPro, announced Wednesday that its Board of Directors approved changes to its executive leadership team as part of an internal realignment. According to a statement released through a SEC filing, David F. Novack will transition from his current positions as President and Chief Operating Officer to the role of Senior Vice President and Chief Operating Officer, effective January 1, 2026.

The company also reported that Robert Janssen, M.D., will be removed from his positions as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs. This change will take effect either when a new Chief Medical Officer is appointed or on March 2, 2026, whichever occurs first. Dr. Janssen’s employment with Dynavax is set to conclude as of March 2, 2026.

Dynavax has started a search process to identify a successor for the Chief Medical Officer position.

These details are based on a press release statement included in the company’s SEC filing. Dynavax Technologies’ common stock is listed on the Nasdaq Global Select Market under the symbol DVAX.

In other recent news, Dynavax Technologies has announced positive topline results from its Phase 1/2 clinical trial for Z-1018, its experimental shingles vaccine candidate. The trial results revealed that Z-1018 achieved comparable immune responses to GlaxoSmithKline’s Shingrix, while demonstrating a significantly better tolerability profile. The vaccine also achieved a 100% humoral vaccine response rate compared to 96.9% for Shingrix. Following this announcement, TD Cowen reiterated its Buy rating with a $25.00 price target, citing the positive topline data. Citizens JMP also maintained its Market Outperform rating and a $32.00 price target, expressing optimism about the vaccine’s tolerability results and CD4+ T-cell responses. However, Goldman Sachs maintained its Sell rating with an $11.00 price target despite the positive trial data. The firm acknowledged the superior tolerability of Z-1018 compared to Shingrix while maintaining non-inferiority on efficacy measures. These developments reflect the mixed analyst sentiment regarding Dynavax Technologies’ recent clinical trial outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.